Entity:UAM. Departamento de Medicina; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD)
UAM Author:Ruiz Ortega, Marta ; Rodrigues Díez, Raúl
Publisher:MDPI, Basel, SMwitzerland
Date:2020-03-15
Citation:
10.3390/jcm9030813
Journal of Clinical Medicine 9.3 (2020): 813
ISSN:2077-0383
DOI:10.3390/jcm9030813
Funded by:Editors are funding by Grants from the Instituto de Salud Carlos III(ISCIII) and Fondos FEDER European
Union (PI17/00119 and Red de Investigación Renal (REDINREN): RD16/0009, to M.R-O), Comunidad de Madrid
(“NOVELREN” B2017/BMD-3751 to M.R-O); the José Castillejo grant (CAS19/00133 to R.R.R-D); the “Juan de
la Cierva Formacion” training program of the Ministerio de Economia, Industria y Competitividad (MINECO)
supported the salary of SR-M (FJCI-2016-29050); Sociedad Española de Nefrologia (S.E.N. to M.R-O). Grants PAI
82140017 to C.L. of Chile; IMPROVE-PD project (“Identification and Management of Patients atRisk–Outcome
and Vascular Events in Peritoneal Dialysis”) funding from the European Union’s Horizon 2020 research and
innovation program under the Marie Skłodowska-Curie Grant Agreement No. 812699 to M.R.O.
Project:Gobierno de España. PI17/00119; Gobierno de España. RD16/0009, to M.R-O; Comunidad de Madrid. B2017/BMD-3751/NOVELREN; info:eu-repo/grantAgreement/EC/H2020/812699/EU//MS-C
Diabetic nephropathy (DN) is the main cause of end-stage renal disease. DN is a complex
disease mediated by genetic and environmental factors, and many cellular and molecular mechanisms
are involved in renal damage in diabetes. There are no biomarkers that reflect the severity of the
underlying renal histopathological changes and can e ectively predict the progression of renal
damage and stratify the risk of DN among individuals with diabetes mellitus. Current therapeutic
strategies are based on the strict control of glucose and blood pressure levels and, although there
are new anti-diabetic drugs, these treatments only retard renal damage progression, being necessary
novel therapies. In this Special Issue, there are several comprehensive reviews and interesting original
papers covering all these topics, which would be of interest to the growing number of readers of the Journal of Clinical Medicine